Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal composition for treating vulvovaginal candidiasis

A technology for vaginal candidiasis and a composition is applied in the field of pharmacy, which can solve the problems of less obvious effect of vaginal inflammation, poor treatment effect, large clinical failure and the like, and achieve the effect of good clinical application prospect.

Active Publication Date: 2013-06-05
兆科药业(广州) +1
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Azole antifungal drugs may kill organisms, but they are not effective for some Candida albicans and non-Candida infections, and the possibility of clinical failure is high. Drugs like fluconazole are effective for treatment and The effect of inhibiting Candida albicans and vaginal inflammation caused by Candida albicans is less obvious

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for treating vulvovaginal candidiasis
  • Medicinal composition for treating vulvovaginal candidiasis
  • Medicinal composition for treating vulvovaginal candidiasis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Embodiment 1 The suppository preparation of pharmaceutical composition of the present invention

[0020] (1) Prescription of 100 vaginal suppositories of the pharmaceutical composition of the present invention:

[0021] Element

Dosage

Sepravatide

0.20g

[0022] gelatin

60g

Glycerin

240g

polyethylene glycol 400

50g

Ethylparaben

0.20g

NaOH

Adjust pH to 4.3±0.1

purified water

About 50ml, add to 400g

[0023] (2) Preparation process

[0024] Take the prescribed amount of gelatin and add an appropriate amount of purified water to infiltrate and swell, add glycerin, polyethylene glycol 400 and ethylparaben, and stir evenly; take the prescribed amount of selepravatide, add an appropriate amount of purified water to dissolve and prepare selepravatide Peptide solution, add this solution to the aforementioned matrix, stir thoroughly for 5 minutes and mix well; add 1mol / L ...

Embodiment 2

[0025] Example 2 In vitro antibacterial test of selepravatide

[0026] (1) Purpose of the test

[0027] To investigate the inhibition degree of different concentrations of selepravatide on the growth of Candida albicans.

[0028] (2) Test method

[0029] Pick the strains and culture them in 100ml fungal medium for 24 hours; pipette 0.5ml bacterial liquid into the liquid medium, add four concentrations (10 -8 、10 -7 、10 -6 、10 -5 mol / L, equivalent to 0.01, 0.1, 1.0, 10.0mg / ml) of selepravatide solution 1.0ml, another sample was added to the bacterial culture medium as a blank control; cultured for 2 hours at 28°C. After 2 hours of cultivation, the bacterial solution was diluted to an appropriate concentration with 0.9% physiological saline; 1.0 ml of the diluted solution was spread on an agar plate, the number of colonies was observed, and the bacteriostatic rate was calculated.

[0030] (3) Test results

[0031] As shown in Table 1.

[0032] Table 1. In vitro bacterios...

Embodiment 3

[0036] Example 3 Pharmacodynamic test of selepravatide in the treatment of rat Candida albicans vaginitis

[0037] (1) Purpose of the test

[0038] To study the therapeutic effect of selepravatide on rat Candida albicans vaginitis.

[0039] (2) Test method

[0040] A, rat Candida albicans vaginitis model construction:

[0041] i. Bilateral ovariectomy of model rats: Take a number of sexually mature immature female healthy Wistar rats weighing 80-100 g, intraperitoneally anesthetize with 7% chloral hydrate (0.5ml / 100g), and remove both ovaries under aseptic conditions. Intramuscular injection of penicillin 100,000 U / cause was given once a day for 3 consecutive days to prevent infection.

[0042] ii. To create false estrus, resulting in low immune function: On the 7th day after the operation, estradiol valerate was given by intragastric administration, 800 μg / 100g per day, for 4 consecutive days.

[0043] iii. Infection process: Candida albicans cells (clinically isolated va...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicinal composition for treating vulvovaginal candidiasis. The composition comprises 0.02 to 0.5 weight percent of Silaipufa peptide or pharmaceutically acceptable salt or ester, and pharmaceutically acceptable excipient and / or carrier. The invention also provides application of the Silaipufa peptide or pharmaceutically acceptable salt or ester in preparation of a medicament for treating the vulvovaginal candidiasis. The Silaipufa peptide can effectively inhibit the activity of candida albicans in vivo and in vitro, is used for local delivery of vulva, can effectively treat the vulvovaginal candidiasis, does not have side effect, and has a broad application prospect.

Description

technical field [0001] The invention relates to the field of pharmacy, in particular to a pharmaceutical composition for treating vulvovaginal candidiasis. Background technique [0002] Vulvovaginal candidiasis (VVC) is inflammation of the vulva and vagina caused by Candida invading the vulva and / or vaginal mucosa cells. It is a common vaginitis second only to bacterial vaginosis. It used to be called fungal vaginitis, candidal vaginitis, etc. Its pathogen is yeast in fungi, among which Candida albicans is the main species. Accounted for 80% to 90%, non-albicans such as Candida glabrata (C.torulopsisglabrata), Candida tropicalis (C.tropicalis), Candida parapsilosis (C.parapsilosis) accounted for a minority. The symptoms shown by the disease are more serious, the incidence rate is high, and it is very easy to relapse after treatment. According to statistics, 75% of women will be infected with VVC at least once in their lifetime, 40% to 50% of women will be infected twice or...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/08A61P31/10A61P31/02A61P15/00
Inventor 李小羿张国辉戴向荣凌娟胡代娣
Owner 兆科药业(广州)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com